3:42 PM
Dec 05, 2018
 |  BC Extra  |  Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said late Wednesday that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the product led to a lower improvement on the primary endpoint of overall survival (OS) vs. topotecan.

The failure is the second setback this year for the product, which was the centerpiece of AbbVie's 2016 acquisition of Stemcentrx Inc. for $5.8...

Read the full 350 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >